Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18804
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKapetanos, D.en
dc.contributor.authorChristodoulou, D.en
dc.contributor.authorChatzizisi, O.en
dc.contributor.authorSigounas, D.en
dc.contributor.authorVasiliou, K.en
dc.contributor.authorStavropoulou, E.en
dc.contributor.authorKatodritou, E.en
dc.contributor.authorKokozidis, G.en
dc.contributor.authorKiriazis, G.en
dc.contributor.authorKitis, G.en
dc.contributor.authorTsianos, E.en
dc.date.accessioned2015-11-24T18:55:05Z-
dc.date.available2015-11-24T18:55:05Z-
dc.identifier.issn1473-5687-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18804-
dc.rightsDefault Licence-
dc.subjectAcute Diseaseen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBiological Markers/blooden
dc.subjectCholangiopancreatography, Endoscopic Retrograde/*adverse effectsen
dc.subjectFemaleen
dc.subjectGastrointestinal Agents/therapeutic useen
dc.subjectHumansen
dc.subjectInflammation Mediators/blooden
dc.subjectInterleukin-6/*blooden
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOctreotide/*therapeutic useen
dc.subjectPancreatitis/*etiology/prevention & controlen
dc.subjectPentoxifylline/*therapeutic useen
dc.subjectTumor Necrosis Factor-alpha/*blood/drug effectsen
dc.titleRandomized study of the effect of pentoxifylline or octreotide on serum levels of TNF-alpha and IL-6 after endoscopic retrograde cholangiopancreatographyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19373973-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractOBJECTIVES: To study the effect of pentoxifylline and octreotide administration on serum levels of TNF-alpha and IL-6, in patients who underwent endoscopic retrograde cholangiopancreatography (ERCP), whether they developed pancreatitis or not. METHODS: Out of 590 patients undergoing ERCP, 30 who developed pancreatitis and 25 who did not (controls) were enrolled. Pentoxifylline was given to 23 patients (15 with and eight without pancreatitis) and octreotide to 19 patients (nine with and 10 without pancreatitis, respectively). Thirteen patients did not receive any preventive medication (six with and seven without pancreatitis, respectively). Blood samples were collected at baseline, 6 and 24 h after ERCP. RESULTS: IL-6 increased significantly in patients with pancreatitis at the 6 h (4.2 pg/ml SD: 5.8) and at the 24 h (6.6 pg/ml SD: 9.8) compared with patients without pancreatitis at the 6 h (2.1 pg/ml SD: 3.6) and 24 h (1.9 pg/ml SD: 2.5) (P < 0.01). No significant difference in the values of TNF-alpha and IL-6 obtained among the three study groups in patients with or without pancreatitis was observed. TNF-alpha levels at the 24 h were lower than baseline in patients with pancreatitis who received octreotide (P = 0.04). CONCLUSION: IL-6 increased in the first 24 h of post-ERCP pancreatitis. Pentoxifylline and octreotide cannot prevent IL-6 elevation but octreotide reduces TNF-alpha levels, which may have an impact on the severity of post-ERCP pancreatitis.en
heal.journalNameEur J Gastroenterol Hepatolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons